See more : First Commerce Bank (CMRB) Income Statement Analysis – Financial Results
Complete financial analysis of Syndax Pharmaceuticals, Inc. (SNDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Syndax Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- STI India Limited (STINDIA.NS) Income Statement Analysis – Financial Results
- Retech Technology Co., Limited (RTE.AX) Income Statement Analysis – Financial Results
- CSP Inc. (CSPI) Income Statement Analysis – Financial Results
- Medigus Ltd. WT C EXP 072323 (MDGSW) Income Statement Analysis – Financial Results
- Atico Mining Corporation (ATCMF) Income Statement Analysis – Financial Results
Syndax Pharmaceuticals, Inc. (SNDX)
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 139.71M | 1.52M | 1.52M | 1.52M | 2.11M | 1.22M | 627.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 12.00K | 454.00K | 456.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 51.00K |
| Gross Profit | -12.00K | -454.00K | 139.25M | 1.52M | 1.52M | 1.52M | 2.11M | 1.22M | 627.00K | 0.00 | 0.00 | 0.00 | -51.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 99.67% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 163.02M | 118.50M | 88.25M | 50.44M | 42.99M | 60.11M | 48.20M | 31.67M | 9.55M | 10.18M | 3.21M | 5.24M | 6.09M |
| General & Administrative | 0.00 | 33.26M | 25.24M | 22.51M | 16.06M | 17.29M | 15.86M | 13.32M | 11.59M | 11.16M | 5.36M | 3.49M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 66.92M | 33.26M | 25.24M | 22.51M | 16.06M | 17.29M | 15.86M | 13.32M | 11.59M | 11.16M | 5.36M | 3.49M | 3.49M |
| Other Expenses | 0.00 | 2.42M | -1.29M | -1.74M | 1.49M | 1.92M | 1.15M | -706.00K | -37.00K | 4.00K | -3.01M | -1.00K | 0.00 |
| Operating Expenses | 229.95M | 151.76M | 113.49M | 72.94M | 59.06M | 77.39M | 64.06M | 44.99M | 21.14M | 21.33M | 8.57M | 8.73M | 9.57M |
| Cost & Expenses | 229.95M | 151.76M | 113.49M | 72.94M | 59.06M | 77.39M | 64.06M | 44.99M | 21.14M | 21.33M | 8.57M | 8.73M | 9.62M |
| Interest Income | 21.16M | 5.87M | 403.00K | 841.00K | 1.57M | 0.00 | 0.00 | 0.00 | 161.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 208.00K | 3.14M | 1.90M | 2.36M | 1.57M | 1.94M | 1.42M | 956.00K | 1.58M | 0.00 | 0.00 | 0.00 | 1.99M |
| Depreciation & Amortization | 12.00K | 454.00K | 456.00K | 515.00K | 451.00K | 78.00K | 76.00K | 89.00K | 21.00K | 15.00K | 13.00K | 34.00K | 51.00K |
| EBITDA | -229.94M | -151.76M | 27.28M | -70.29M | -55.60M | -73.88M | -61.88M | -43.68M | -20.49M | -21.32M | -8.56M | -5.26M | -11.05M |
| EBITDA Ratio | 0.00% | 0.00% | 18.77% | -4,708.17% | -3,792.95% | -5,001.71% | -2,938.99% | -3,587.38% | -3,248.48% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -229.95M | -151.76M | 26.22M | -71.42M | -57.54M | -75.88M | -61.95M | -43.77M | -20.51M | -21.33M | -8.57M | -8.73M | -9.62M |
| Operating Income Ratio | 0.00% | 0.00% | 18.77% | -4,708.17% | -3,792.95% | -5,001.71% | -2,938.99% | -3,587.38% | -3,271.61% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 20.59M | 2.42M | -1.29M | -1.74M | 1.49M | 1.92M | 1.15M | -706.00K | -3.61M | 1.50M | -5.60M | -1.23M | -3.47M |
| Income Before Tax | -209.36M | -149.34M | 24.93M | -73.16M | -56.05M | -73.96M | -60.80M | -44.47M | -24.12M | -19.83M | -14.17M | -9.97M | -13.09M |
| Income Before Tax Ratio | 0.00% | 0.00% | 17.84% | -4,822.54% | -3,694.59% | -4,875.48% | -2,884.35% | -3,645.25% | -3,846.73% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -5.59M | -43.00K | -89.00K | -92.00K | 1.92M | -76.00K | -89.00K | 1.54M | -1.50M | 2.59M | 1.23M | 0.00 |
| Net Income | -209.36M | -143.75M | 24.93M | -73.07M | -55.96M | -73.96M | -60.80M | -44.47M | -24.12M | -19.83M | -14.17M | -9.97M | -13.09M |
| Net Income Ratio | 0.00% | 0.00% | 17.84% | -4,816.68% | -3,688.53% | -4,875.48% | -2,884.35% | -3,645.25% | -3,846.73% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.98 | -2.37 | 0.48 | -1.77 | -1.84 | -2.92 | -2.90 | -3.04 | -1.39 | -2.07 | -1.77 | -0.14 | -21.11 |
| EPS Diluted | -2.98 | -2.37 | 0.46 | -1.77 | -1.84 | -2.92 | -2.90 | -3.04 | -1.39 | -2.07 | -1.77 | -0.14 | -21.11 |
| Weighted Avg Shares Out | 70.26M | 60.76M | 52.06M | 41.31M | 30.49M | 25.37M | 21.00M | 14.62M | 17.37M | 9.60M | 8.01M | 70.28M | 619.96K |
| Weighted Avg Shares Out (Dil) | 70.37M | 60.76M | 53.62M | 41.31M | 30.49M | 25.37M | 21.00M | 14.62M | 17.37M | 9.60M | 8.01M | 70.28M | 619.96K |
Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
– New monotherapy and combination data in acute leukemia further highlight revumenib's compelling clinical profile – – 64% ORR (62/97) in expanded dataset of patients with R/R KMT2Ar acute leukemia in Ph 2 AUGMENT-101 pivotal cohort – – 88% ORR (23/26)...
Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting
– Rapid responses and symptom improvement observed in inflammatory and fibrotic manifestations of chronic GVHD in heavily pretreated patients – WALTHAM, Mass. , Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq:SNDX), today announced that multiple abstracts evaluating Niktimvo™ (axatilimab-csfr), an...
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™
Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenib Expected to fund Company through profitability; proforma cash approaching $800 million as of June 30 WALTHAM, Mass. and NEW YORK , Nov. 4,...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass. , Nov. 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on November 1, 2024 the Company granted inducement awards to purchase up to 78,700 shares...
Syndax Announces Participation in November Investor Conferences
WALTHAM, Mass. , Nov. 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A.
Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024
WALTHAM, Mass. , Oct. 29, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its third quarter 2024 financial results and provide a business update...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass. , Oct. 4, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on October 1, 2024 the Company granted inducement awards to purchase up to 62,700 shares...
Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease
– Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg every 2 weeks dose achieving a complete or partial response within the first six months of treatment – – Niktimvo approved by...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass. , Sept. 6, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on September 1, 2024 the Company granted an inducement award to purchase up to...
Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia
– Pivotal AUGMENT-101 trial met its primary endpoint at interim analysis of patients with KMT2Ar AML and ALL (p-value = 0.0036) – – NDA filing for revumenib in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26,...
Source: https://incomestatements.info
Category: Stock Reports